ALRN — Aileron Therapeutics Share Price
0.000.00%
Last trade - 00:00- $80.45m
- $68.38m
- 22
- 10
- 93
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.18 | ||
| Price to Tang. Book | 7.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -122.25% | ||
| Return on Equity | -76.36% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Directors
- Jeffrey Bailey NEC (59)
- Manuel Alves Aivado PRE (50)
- Rick Wanstall CFO (52)
- D. Allen Annis SVP (48)
- Vojislav Vukovic SVP (54)
- Reinhard Ambros IND (66)
- William Mckee IND (59)
- Jodie Morrison IND (45)
- Nolan Sigal IND (71)
- Josef Von Rickenbach IND (66)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- August 6th, 2001
- Public Since
- June 29th, 2017
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,972,512
- Address
- 12407 N. Mopac Expy., Suite 250 #390, AUSTIN, 78758
- Web
- https://aileronrx.com/
- Phone
- +1 6179950900
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ALRN
Q2 2024 Aileron Therapeutics Inc Earnings Release
Q3 2024 Aileron Therapeutics Inc Earnings Release
Similar to ALRN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Aileron Therapeutics share price?
As of Today at 19:00 UTC, shares in Aileron Therapeutics are trading at $4.74. This share price information is delayed by 15 minutes.
How has the Aileron Therapeutics share price performed this year?
Shares in Aileron Therapeutics last closed at $4.74 and the price had moved by +211.84% over the past 365 days. In terms of relative price strength the Aileron Therapeutics share price has outperformed the S&P500 Index by +159.5% over the past year.
What are the analyst and broker recommendations for Aileron Therapeutics?
The overall consensus recommendation for Aileron Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aileron Therapeutics dividend yield?
Aileron Therapeutics does not currently pay a dividend.
Does Aileron Therapeutics pay a dividend?
Aileron Therapeutics does not currently pay a dividend.
When does Aileron Therapeutics next pay dividends?
Aileron Therapeutics does not currently pay a dividend.
How do I buy Aileron Therapeutics shares?
To buy shares in Aileron Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aileron Therapeutics?
As of the previous close price of $4.74, shares in Aileron Therapeutics had a market capitalisation of $80.45m.
Where are Aileron Therapeutics shares listed?
Here are the trading details for Aileron Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ALRN
What kind of share is Aileron Therapeutics?
Based on an overall assessment of its quality, value and momentum Aileron Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aileron Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Aileron Therapeutics is $19.00. That is 300.84% above the last closing price of $4.74.
Analysts covering Aileron Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.01 for the next financial year.
What is the trend in the Aileron Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aileron Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +219.38%.
As of the last closing price of $4.74, shares in Aileron Therapeutics were trading +57.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aileron Therapeutics PE Ratio?
The Aileron Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aileron Therapeutics?
Aileron Therapeutics' management team is headed by:
- Jeffrey Bailey - NEC
- Manuel Alves Aivado - PRE
- Rick Wanstall - CFO
- D. Allen Annis - SVP
- Vojislav Vukovic - SVP
- Reinhard Ambros - IND
- William Mckee - IND
- Jodie Morrison - IND
- Nolan Sigal - IND
- Josef Von Rickenbach - IND